30 results on '"Herzog, C E"'
Search Results
2. An erythematous plaque on the face
- Author
-
Wyatt, A. J., Herzog, C. E., and Lazar, A. J. F.
- Published
- 2007
3. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach
- Author
-
Hayes-Jordan, Andrea, primary, Lopez, C., additional, Green, H. L., additional, Xiao, L. C., additional, Huh, W., additional, and Herzog, C. E., additional
- Published
- 2015
- Full Text
- View/download PDF
4. Novel phase I clinical trials in sarcoma patients: The M. D. Anderson Cancer Center experience.
- Author
-
Subbiah, V., primary, Benjamin, R. S., additional, Naing, A., additional, Trent, J. C., additional, Hong, D. S., additional, Pinnamaneni, P., additional, Garrido-Laguna, I., additional, Herzog, C. E., additional, Kleinerman, E., additional, and Kurzrock, R., additional
- Published
- 2010
- Full Text
- View/download PDF
5. Pediatric salivary gland neoplasms: The M. D. Anderson Cancer Center experience
- Author
-
Huh, W. W., primary, Bosworth, C., additional, Hessel, A. C., additional, Mahajan, A., additional, Hughes, D. P., additional, and Herzog, C. E., additional
- Published
- 2007
- Full Text
- View/download PDF
6. An erythematous plaque on the face
- Author
-
Wyatt, A. J., primary, Herzog, C. E., additional, and Lazar, A. J. F., additional
- Published
- 2006
- Full Text
- View/download PDF
7. Comparison of doxorubicin cardiotoxicity in pediatric patients when given with dexrazoxane versus a continuous infusion
- Author
-
Herzog, C. E., primary, Huh, W., additional, Jaffe, N., additional, and Durand, J., additional
- Published
- 2006
- Full Text
- View/download PDF
8. #662 Sequential high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for pediatric solid tumors (ST)
- Author
-
Petropoulos, D., primary, Ater, J. L., additional, Herzog, C. E., additional, Jaffe, N., additional, Rancy, R. B., additional, and Chan, K. W., additional
- Published
- 1996
- Full Text
- View/download PDF
9. Various Methods of Analysis of mdr-1/P-Glycoprotein in Human Colon Cancer Cell Lines
- Author
-
Herzog, C. E., primary, Trepel, J. B., additional, Mickley, L. A., additional, Bates, S. E., additional, and Fojo, A. T., additional
- Published
- 1992
- Full Text
- View/download PDF
10. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
- Author
-
Asano, T, Zwelling, LA, An, T, McWatters, A, Herzog, CE, Mayes, J, Loughlin, SM, Kleinerman, ES, Zwelling, L A, Herzog, C E, Loughlin, S M, and Kleinerman, E S
- Published
- 1996
- Full Text
- View/download PDF
11. A Half Century of Experience With Carcinoid Tumors in Children
- Author
-
Corpton, C. A., Black, C. T., Herzog, C. E., Sellin, R. V., Lally, K. P., and Andrassy, R. J.
- Published
- 1995
- Full Text
- View/download PDF
12. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
- Author
-
Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, and Subbiah V
- Subjects
- Humans, Young Adult, Adolescent, Child, Vascular Endothelial Growth Factor A, Sirolimus adverse effects, Piperidines adverse effects, Quinazolines adverse effects, Everolimus adverse effects, Neoplasms drug therapy, Neoplasms genetics
- Abstract
Background: Combined use of inhibitors of mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF-2) receptors is a potential strategy to overcome resistance to either class of drugs when used alone., Patients and Methods: We designed a phase 1 trial to test the drug combination of a multikinase VEGF receptor 2 inhibitor, vandetanib, and an mTOR inhibitor, everolimus, in a pediatric and young adult patient cohort with advanced cancers. Exceptional responders were probed for tumor mutational profile to explore possible molecular mechanisms of response., Results: Among 21 enrolled patients, clinical benefit was observed in 38% (one patient with partial response and eight patients with stable disease) with a median progression-free survival of 3.3 months. The most common treatment-related adverse event was rash (n = 13). Other treatment-related toxicities included diarrhea, fatigue, hypertension, QT prolongation, hypertriglyceridemia/hypercholesterolemia, transaminitis, thrombocytopenia, and weight loss. None of the patients experienced dose-limiting toxicities. Three exceptional responders were analyzed and were found to harbor genetic alterations including kinase insert domain receptor (KDR) Q472H mutation, EWSR1-CREB3L1, CDKN2A/B loss, and ASPL/ASPSCR1-TFE3 fusion., Conclusions: The combination of vandetanib and everolimus showed early activity and tolerable toxicity profile in pediatric patients with advanced cancers., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors.
- Author
-
Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, and Gore L
- Subjects
- Adolescent, Antibodies, Monoclonal pharmacokinetics, Child, Child, Preschool, Drug Resistance, Neoplasm, Female, Humans, Male, Recurrence, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Neoplasms drug therapy, Receptor, IGF Type 1 antagonists & inhibitors
- Abstract
Purpose: This pediatric phase I study was designed to identify the doses of RG1507, a monoclonal antibody against the Type 1 Insulin-like Growth Factor Receptor (IGF1R), that achieves exposures equivalent to those achieved in adults at recommended doses., Experimental Design: Children with relapsed or refractory solid tumors were treated using the same doses and administration schedules of RG1507 (3 and 9 mg/kg/wk, and 16 mg/kg every 3 weeks [q3W]) as those studied in adults. Detailed pharmacokinetic (PK) sampling was performed after the first dose; selected peak and trough levels were subsequently obtained. Target exposures were ≥85% of mean areas under concentration x time curves (AUCs) in adults at doses of 9 mg/kg/wk and 16 mg/kg q3W. A maximum tolerated dose could be identified if dose-limiting toxicities (DLT) occurred., Results: Thirty-one evaluable patients aged 3-17 years were enrolled at 3 mg/kg/wk (n = 3), 9 mg/kg/wk (n = 18), or 16 mg/kg q3W (n = 10). There were no DLTs. At 9 mg/kg/wk the mean AUC(0-7d) (21,000 μg h/mL) exceeded the target (16,000 μg h/mL). At 16 mg/kg q3W, the mean AUC(021d) (70,000 μg h/mL) exceeded the target (59,400 μg h/mL). Clearance normalized to body weight was age dependent. There were no objective responses. Seven patients had stable disease for >12 weeks, including two patients with osteosarcoma with stable disease for 52+ and 78+ weeks., Conclusions: The recommended doses of RG1507 in children with solid tumors are 9 mg/kg/wk and 16 mg/kg q3W. This flexible design is well suited for trials of agents associated with limited toxicity., (©2010 AACR.)
- Published
- 2011
- Full Text
- View/download PDF
14. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
- Author
-
Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, and Pisters PW
- Subjects
- Adult, Aged, Child, Child, Preschool, Combined Modality Therapy, Female, Histiocytoma, Benign Fibrous therapy, Humans, Infant, Male, Middle Aged, Rhabdomyosarcoma therapy, Sarcoma, Ewing therapy, Treatment Outcome, Antineoplastic Agents, Alkylating administration & dosage, Bone Neoplasms therapy, Ifosfamide administration & dosage, Sarcoma therapy, Soft Tissue Neoplasms therapy
- Abstract
Background: The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas., Methods: The medical records of 43 consecutive patients with soft tissue or bone sarcomas who were treated with concurrent IFX and EBRT were reviewed., Results: The median patient age was 20 years. Histologies were rhabdomyosarcoma (n = 16 patients), Ewing sarcoma (n = 10 patients), malignant fibrous histiocytoma (n = 9 patients), and other soft tissue sarcomas (n = 8 patients). Thirty-one patients (72%) had localized disease, and 12 patients (28%) had synchronous local and distant disease. Treatment consisted of EBRT (median dose, 50.4 gray [Gy]) with concomitant IFX (median dose per cycle, 10.2 g/m(2)). All patients with Ewing sarcoma or rhabdomyosarcoma received additional concurrent chemotherapy. Twenty-six patients (60%) received two or more cycles of IFX, and 17 patients (40%) were treated with one cycle of IFX and EBRT. The incidences of World Health Organization Grade 3 and Grade 4 toxicities were 29% (21 of 73 cycles) and 22% (16 of 73 cycles), respectively. Grade 4 systemic toxicities included leukopenia (n = 14 patients), neurotoxicity (suicidal ideation; n = 1 patient), and diarrhea (n = 1 patient). Confluent moist desquamation (Grade 3) occurred in nine patients in the treatment field; no patient experienced Grade 4 local toxicity. Among 14 patients who were treated preoperatively, 2 patients (14%) had a pathologic complete response, and 6 patients (43%) had a pathologic near-complete response (> or = 90% necrosis)., Conclusions: Local and systemic toxicities after the administration of therapeutic doses of IFX with concomitant EBRT appear comparable to those observed with either treatment alone. These results support the design of prospective studies evaluating concurrent ifosfamide and radiation therapy for patients with sarcomas., (Copyright 2001 American Cancer Society.)
- Published
- 2001
- Full Text
- View/download PDF
15. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
- Author
-
Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, and Gorlick RG
- Subjects
- Adolescent, Adult, Bone Neoplasms pathology, Child, Child, Preschool, Disease Progression, Dose-Response Relationship, Drug, Etoposide administration & dosage, Female, Humans, Infant, Male, Melphalan administration & dosage, Neoplasm Metastasis, Prognosis, Sarcoma, Ewing pathology, Transplantation, Autologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Sarcoma, Ewing therapy, Whole-Body Irradiation
- Abstract
Purpose: To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing's sarcoma (ES)., Patients and Methods: Thirty-two eligible patients with newly diagnosed ES metastatic to bone and/or bone marrow were enrolled onto this study. Treatment was initially comprised of five cycles of induction chemotherapy (cyclophosphamide, doxorubicin, and vincristine alternating with ifosfamide and etoposide) and local control. Peripheral-blood stem-cell collection was performed after the second cycle of chemotherapy, with delay if the bone marrow was persistently involved. If patients had a good response to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, and stem-cell support., Results: Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation. Of the nine patients who did not proceed to consolidation, four were secondary to progressive disease and two were secondary to toxicity. Three patients died from toxicity during the high-dose phase of the therapy. The majority of the patients who underwent high-dose consolidation therapy experienced relapse and died with progressive disease. Two-year event-free survival (EFS) for all eligible patients is 20%. The 2-year post-stem-cell reconstitution EFS for the subset of 23 patients who received consolidation therapy is 24%. Analysis of peripheral-blood stem-cell collections by molecular techniques for minimal residual disease showed contamination of at least some samples by tumor cells in all three patients with available data., Conclusion: Consolidation with high-dose melphalan, etoposide, TBI, and autologous stem-cell support failed to improve the probability of EFS in this cohort of patients with newly diagnosed metastatic ES.
- Published
- 2001
- Full Text
- View/download PDF
16. Drug-induced cytotoxicity in tissue culture.
- Author
-
Herzog CE and Zwelling LA
- Subjects
- Agar, Animals, Cell Count, Cell Death drug effects, Cell Division drug effects, Cell Line, Cell Survival drug effects, Clone Cells cytology, Clone Cells drug effects, Clone Cells enzymology, Clone Cells metabolism, DNA metabolism, DNA Damage drug effects, DNA Topoisomerases, Type II metabolism, Tetrazolium Salts metabolism, Thiazoles metabolism, Antineoplastic Agents toxicity, Topoisomerase II Inhibitors
- Published
- 2001
- Full Text
- View/download PDF
17. Childhood cancers: hepatoblastoma.
- Author
-
Herzog CE, Andrassy RJ, and Eftekhari F
- Subjects
- Child, Hepatoblastoma diagnosis, Hepatoblastoma pathology, Humans, Liver Neoplasms diagnosis, Liver Neoplasms pathology, Neoplasm Staging, Hepatoblastoma therapy, Liver Neoplasms therapy
- Abstract
Hepatoblastoma is the most common primary liver tumor in children, accounting for just over 1% of pediatric cancers. The etiology is unknown, but it has been associated with Beckwith-Weidemann syndrome, familial adenomatosis polypi, and low birth weight. The primary treatment is surgical resection, however, chemotherapy plays an important role by increasing the number of tumors that are resectable. The prognosis for patients with resectable tumors is fairly good, however, the outcome for those with nonresectable or recurrent disease is poor.
- Published
- 2000
- Full Text
- View/download PDF
18. Congenital hepatoblastoma and schizencephaly in an infant with Beckwith-Wiedemann syndrome.
- Author
-
Worth LL, Slopis JM, and Herzog CE
- Subjects
- Beckwith-Wiedemann Syndrome pathology, Brain pathology, Hepatoblastoma congenital, Hepatoblastoma surgery, Hepatoblastoma therapy, Humans, Infant, Newborn, Liver Neoplasms congenital, Liver Neoplasms surgery, Liver Neoplasms therapy, Magnetic Resonance Imaging, Male, Seizures complications, Beckwith-Wiedemann Syndrome complications, Brain abnormalities, Hepatoblastoma complications, Liver Neoplasms complications
- Published
- 1999
- Full Text
- View/download PDF
19. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma.
- Author
-
Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, and Wharton JT
- Subjects
- Adolescent, Adult, Bleomycin administration & dosage, Child, Cisplatin administration & dosage, Disease-Free Survival, Dysgerminoma surgery, Etoposide administration & dosage, Female, Follow-Up Studies, Humans, Neoplasms, Second Primary drug therapy, Ovarian Neoplasms surgery, Ovariectomy, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols pharmacology, Dysgerminoma drug therapy, Menstrual Cycle drug effects, Ovarian Neoplasms drug therapy, Pregnancy Rate
- Abstract
Purpose: To review the outcome for all patients with ovarian dysgerminoma treated at the M.D. Anderson Cancer Center who received bleomycin, etoposide, and cisplatin (BEP) and to assess the menstrual and reproductive function of those who received conservative treatment., Patients and Methods: Clinical information was abstracted from the medical record. Patients completed a detailed questionnaire about menstrual and reproductive function; those who did not return the questionnaire were interviewed by telephone., Results: Twenty-six patients were identified as having been treated with BEP chemotherapy for pure ovarian dysgerminoma from January 1984 to January 1998. Their median age was 19.5 years (range, 7 to 32 years). Sixteen patients underwent fertility-sparing surgery in the form of unilateral salpingo-oophorectomy. At a median follow-up time of 89 months, 25 (96%) of the 26 patients remained continuously disease-free. One patient apparently developed a second primary dysgerminoma in her remaining ovary after BEP and was clinically disease-free after further treatment. Of the 16 patients who underwent fertility-sparing surgery, one was lost to follow-up when she was pregnant, and one was still premenarchal. Of the remaining 14 patients, 10 (71%) maintained their normal menstrual function during and after chemotherapy, and 13 (93%) had returned to their prechemotherapy menstrual pattern at the time of the questionnaire. Five pregnancies have occurred thus far, and two patients have had difficulty conceiving., Conclusion: Most patients with metastatic dysgerminoma can expect cure with maintenance of normal reproductive function when treated with conservative surgery and BEP chemotherapy.
- Published
- 1999
- Full Text
- View/download PDF
20. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
- Author
-
Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, and Zwelling LA
- Subjects
- Antigens, Neoplasm, Blotting, Northern, Blotting, Southern, DNA-Binding Proteins, Drug Resistance, Neoplasm, HL-60 Cells drug effects, HL-60 Cells enzymology, Humans, Immunoblotting, Isoenzymes biosynthesis, Isoenzymes metabolism, Mutation, Phenotype, RNA, Messenger metabolism, Amsacrine pharmacology, Antineoplastic Agents pharmacology, DNA Topoisomerases, Type II biosynthesis, DNA Topoisomerases, Type II deficiency, DNA Topoisomerases, Type II genetics, DNA Topoisomerases, Type II metabolism, Isoenzymes genetics
- Abstract
Numerous chemotherapeutic agents act via stabilization of a topoisomerase (topo) II-DNA complex. HL-60/AMSA, a human leukemia cell line, is resistant to intercalator-mediated DNA complex formation and cytotoxicity. HL-60/AMSA contains a mutant form of topo IIalpha that was thought to explain this resistance. However, our present data show that expression of topo IIbeta RNA in HL-60/AMSA is only 10% of that in HL-60, and topo IIbeta protein levels are undetectable. Southern analysis of topo IIbeta shows no differences in gene dosage between the two cell lines but does show differences in the restriction patterns. These data suggest that decreased topo IIbeta expression may contribute to the intercalator resistance of HL-60/AMSA cells.
- Published
- 1998
21. Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoter.
- Author
-
Herzog CE and Zwelling LA
- Subjects
- Antigens, Neoplasm, Base Sequence, Binding Sites genetics, Binding, Competitive, DNA genetics, DNA isolation & purification, DNA metabolism, DNA-Binding Proteins, Electrophoresis, Polyacrylamide Gel, HL-60 Cells, Humans, Mutation, Protein Binding, DNA Topoisomerases, Type II genetics, Isoenzymes genetics, Promoter Regions, Genetic
- Abstract
Several chemotherapeutic agents act via inhibition of topoisomerase (topo) II activity. Topo II levels appear to correlate with drug sensitivity in vivo. The DNA immediately 5' to the topo II alpha coding region contains five potentially regulatory inverted CCAAT boxes (ICB). Electrophoretic mobility shift assays (EMSA) using oligomers containing the wild type forms of these ICBs show specific DNA-protein binding. Mutations in these ICBs result in loss of protein binding. EMSA competition studies indicate that the four most 3' ICBs (1-4) bind to the same protein(s), while the most 5' ICB (5) binds to a different protein(s). EMSA supershift assays with antibodies to two known CCAAT binding proteins, CBF and CEB/P, indicate that ICBs 1-4 are binding to CBF, but ICB 5 is not bound by either of these proteins.
- Published
- 1997
- Full Text
- View/download PDF
22. A half century of experience with carcinoid tumors in children.
- Author
-
Corpron CA, Black CT, Herzog CE, Sellin RV, Lally KP, and Andrassy RJ
- Subjects
- Adolescent, Adult, Child, Female, Humans, Male, Appendiceal Neoplasms diagnosis, Appendiceal Neoplasms surgery, Carcinoid Tumor diagnosis, Carcinoid Tumor surgery
- Abstract
Purpose: To investigate the frequency, presentation, clinical management, and prognosis of appendiceal carcinoid tumors in children., Method: A review of our institution's experience over 50 years., Results: Twenty-two patients below the age of 20 presented with appendiceal carcinoid tumor. The mean age at presentation was 14.6 years. Twelve patients presented with symptoms of appendicitis. No tumor was > 2.0 cm in size. Only 2 patients underwent resection beyond appendectomy. No patient had recurrent or metastatic carcinoid tumor, and all but 1 patient (who died of ovarian choriocarcinoma) are alive without evidence of carcinoid tumors 1.5 to 30 years after diagnosis., Conclusions: Appendiceal carcinoid tumors in children are rarely life-threatening and the incidence of large tumors (> 2.0 cm) is very low. The role of right hemicolectomy in large (> 2.0 cm) tumors is questionable in this age group.
- Published
- 1995
- Full Text
- View/download PDF
23. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
- Author
-
Herzog CE, Zwelling LA, McWatters A, and Kleinerman ES
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Antineoplastic Agents, Phytogenic pharmacokinetics, Brain Neoplasms metabolism, DNA, Neoplasm drug effects, DNA, Neoplasm metabolism, Drug Resistance, Neoplasm, Etoposide pharmacokinetics, Humans, Tumor Cells, Cultured drug effects, Tumor Stem Cell Assay, Antineoplastic Agents, Phytogenic pharmacology, Apoptosis, DNA Topoisomerases, Type II metabolism, Etoposide pharmacology, Neoplasm Proteins metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism, Tumor Suppressor Protein p53 metabolism
- Abstract
We characterized three human brain tumor cell lines (D54, HBT-20, and HBT-28) with respect to resistance to etoposide (VP-16), a topoisomerase II-reactive drug. All three cell lines were inherently resistant to VP-16 when compared to other human cell lines, with D54 showing the greatest resistance using colony formation assays. Resistance to VP-16 has been attributed to decreased drug uptake and changes in topoisomerase II; however, drug uptake and topoisomerase II protein levels (immunoblot) were no lower in D54 than in HBT-20 and HBT-28, cell lines relatively more sensitive to VP-16. More to the point, measurement of topoisomerase II-mediated DNA cleavage of cellular DNA after treatment with VP-16 showed that the topoisomerase II in these cells was active. These data indicate mechanisms other than those attributable to decreased drug uptake or altered topoisomerase II exist for clinical resistance to VP-16. VP-16-induced DNA cleavage has been associated with apoptosis in some cell lines; however, neither DNA laddering nor morphological changes characteristic of apoptosis were detected in these cell lines after treatment with VP-16. Bcl-2 and mutant p53 were present in these cells. Either of these conditions can prevent apoptosis and could explain a dissociation between the proximal mediator of VP-16-induced cytotoxicity (topoisomerase II-DNA complex formation) and cellular death.
- Published
- 1995
24. Soft tissue sarcomas.
- Author
-
Herzog CE
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Dental Care for Chronically Ill, Head and Neck Neoplasms pathology, Head and Neck Neoplasms therapy, Humans, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal pathology, Neoplasms, Germ Cell and Embryonal therapy, Radiotherapy, Rhabdomyosarcoma pathology, Rhabdomyosarcoma therapy, Sarcoma pathology, Urogenital Neoplasms pathology, Urogenital Neoplasms therapy, Sarcoma therapy
- Published
- 1995
25. Intracranial hemangiopericytomas in children.
- Author
-
Herzog CE, Leeds NE, Bruner JM, and Baumgartner JE
- Subjects
- Brain surgery, Brain Neoplasms surgery, Hemangiopericytoma surgery, Humans, Infant, Magnetic Resonance Imaging, Male, Neoplasm Invasiveness, Tomography, X-Ray Computed, Brain pathology, Brain Neoplasms diagnosis, Brain Neoplasms pathology, Hemangiopericytoma diagnosis, Hemangiopericytoma pathology
- Abstract
Hemangiopericytomas (HPs) are rare tumors, about 10% of which occur in children. Since 1988, 2 children with intracranial HP have been seen at the University of Texas M.D. Anderson Cancer Center. The patients presented at ages 2 weeks and 1 month. Both were treated with surgery alone. We also review 4 cases previously reported in the literature; at presentation, those patients were ages 2 days to 9 months. Infantile HPs have a better prognosis than do those that occur in adults, and an improved outcome is also evident for intracranial lesions. Tumors that occur in the neonatal period may be treated with surgery alone; however, those that occur after the neonatal period may be more likely to recur.
- Published
- 1995
- Full Text
- View/download PDF
26. Molecular diagnosis of multidrug resistance.
- Author
-
Herzog CE and Bates SE
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Antineoplastic Agents pharmacology, Flow Cytometry, Gene Expression, Humans, Immunohistochemistry, In Situ Hybridization, Neoplasm Proteins analysis, Neoplasm Proteins genetics, Neoplasms chemistry, Neoplasms drug therapy, Polymerase Chain Reaction, RNA, Messenger analysis, RNA, Neoplasm analysis, Reproducibility of Results, Sensitivity and Specificity, Tumor Cells, Cultured chemistry, ATP Binding Cassette Transporter, Subfamily B, Member 1 analysis, Drug Resistance, Multiple genetics
- Published
- 1994
- Full Text
- View/download PDF
27. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.
- Author
-
Herzog CE, Tsokos M, Bates SE, and Fojo AT
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1, Cell Differentiation drug effects, Cell Division drug effects, Fluorescent Antibody Technique, Gene Expression drug effects, Humans, In Vitro Techniques, Nifedipine pharmacology, RNA, Messenger genetics, RNA, Messenger metabolism, Tumor Cells, Cultured, Verapamil pharmacology, Drug Resistance, Membrane Glycoproteins antagonists & inhibitors, Membrane Glycoproteins genetics
- Abstract
We observed increased levels of mdr-1 mRNA and its protein product P-glycoprotein (Pgp) in the human colon carcinoma cell line, LS 180, and its drug-resistant sublines, LS 180-Ad50 and LS 180-Vb2, after treatment with the Pgp antagonists, verapamil, nifedipine, and cyclosporin A. Increases in mdr-1 RNA were observed within 8 h of the addition of the Pgp antagonists and continued to rise over time. Peak levels were attained after several weeks and were sustained for the duration of treatment up to several months, with a rapid decline in mdr-1 mRNA levels after removal of the Pgp antagonist. Corresponding changes in Pgp were demonstrated with addition and removal of the Pgp antagonists. Increased mdr-1 mRNA was also seen with two other calcium channel blockers, nicardipine and diltiazem, but not with the Pgp antagonists, quinidine and chlorpromazine. Treatment with verapamil or nifedipine was associated with electron microscopic changes consistent with increased differentiation and resulted in increased carcinoembryonic antigen expression, suggesting that the increase in mdr-1 expression was associated with the process of differentiation. Nuclear runoff experiments and inhibition of new RNA synthesis with actinomycin D treatment failed to detect an increase in mdr-1 transcription or stabilization of the mdr-1 mRNA suggesting that the effect of these agents is mediated posttranscriptionally within the nucleus.
- Published
- 1993
28. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines.
- Author
-
Herzog CE, Trepel JB, Mickley LA, Bates SE, and Fojo AT
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1, Flow Cytometry, Gene Expression, Humans, Immunohistochemistry, In Vitro Techniques, Membrane Glycoproteins genetics, Nucleic Acid Hybridization, Polymerase Chain Reaction, RNA, Messenger genetics, RNA, Neoplasm genetics, Tumor Cells, Cultured, Colonic Neoplasms physiopathology, Drug Resistance, Membrane Glycoproteins analysis
- Abstract
Background: Multidrug resistance (MDR) mediated by high levels of mdr-1 (also known as PGY1)/P-glycoprotein (Pgp) has been studied in tissue culture systems; however, most tumor samples which express mdr-1/Pgp have much lower levels., Purpose: We wanted to determine if levels seen clinically could be detected by commonly used methods and to determine if these levels conferred MDR reversible by Pgp antagonists., Methods: We studied multi-drug-resistant cell lines and sublines with levels of mdr-1/Pgp expression comparable to those seen clinically. We evaluated the expression of mdr-1 RNA by Northern blot analysis, slot blot analysis, polymerase chain reaction (PCR) analysis, and in situ hybridization. We evaluated protein expression by immunofluorescence, immunohistochemistry, fluorescence-activated cell sorting, and immunoblotting analyses. Drug resistance and reversibility were determined by cell growth during continuous drug exposure., Results: In most cases, the low level of mdr-1/Pgp present in these cell lines could be detected by each method, but the assays were at the limit of sensitivity for all methods except the PCR method. These low levels of mdr-1/Pgp are capable of conferring MDR, which can be antagonized by verapamil., Conclusions: Levels of mdr-1/Pgp similar to those found in clinical samples can be detected by each of these methods, but the PCR method was the most sensitive and most reliably quantitative., Implications: In vitro sensitization by the addition of verapamil in cell lines with these low levels of mdr-1/Pgp suggests that clinically detected levels may confer drug resistance in vivo.
- Published
- 1992
- Full Text
- View/download PDF
29. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression.
- Author
-
Murphy LD, Herzog CE, Rudick JB, Fojo AT, and Bates SE
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1, Butyrates pharmacology, Butyric Acid, DNA biosynthesis, Deoxycytosine Nucleotides metabolism, Gene Expression drug effects, Humans, RNA, Messenger biosynthesis, Sensitivity and Specificity, Transcription, Genetic, Tumor Cells, Cultured, Membrane Glycoproteins genetics, Polymerase Chain Reaction
- Abstract
The ability of the polymerase chain reaction (PCR) to quantitate expression of mRNA was examined in the present study. The model chosen was expression of the multidrug resistance gene mdr-1/Pgp in two colon carcinoma cell lines which express mdr-1/Pgp at levels comparable to those found in many clinical samples. PCR was utilized to evaluate differences in mdr-1/Pgp expression in the two cell lines after modulation by sodium butyrate. Thus, comparisons were made across a range of mdr-1/Pgp expression as well as comparisons of small differences. The PCR was found to be both sensitive and quantitative. Accurate quantitation requires demonstration of an exponential range which varies among samples. The exponential range can be determined by carrying out the PCR for a fixed number of cycles on serial dilutions of the RNA reverse transcription product, or by performing the reaction with a varying number of cycles on a fixed quantity of cDNA. By quantitation of the difference in PCR product derived from a given amount of RNA from the sodium butyrate treated and untreated cells, the difference in mRNA expression between samples can be determined. Normalization of the results can be achieved by independent amplification of a control gene, such as beta 2-microglobulin, when the latter is also evaluated in the exponential range. Simultaneous amplification of the control and target genes results in lower levels of PCR products due to competition, which varies from sample to sample. The PCR is thus a labor-intensive but sensitive method of quantitating gene expression in small samples of RNA.
- Published
- 1990
- Full Text
- View/download PDF
30. Localization of the L1Md family of repeated sequences in the mouse albumin-alpha-fetoprotein gene complex.
- Author
-
Cooper R, Herzog CE, Li ML, Zapisek WF, Hoyt PR, Ratrie H 3rd, and Papaconstantinou J
- Subjects
- Animals, Cloning, Molecular, DNA analysis, DNA Restriction Enzymes, Mice, Nucleic Acid Hybridization, Repetitive Sequences, Nucleic Acid, Genes, Serum Albumin genetics, alpha-Fetoproteins genetics
- Abstract
Studies on the beta-globin gene complex in the mouse have demonstrated the existence of repeated DNA sequences interspersed throughout the intergenic regions (1,2). These sequences are members of families of middle repetitive sequences and have been mapped to specific intergenic sites in the 60 kbp beta-globin complex. In this study we present evidence that members of this middle repetitive family of DNA sequences, the L1Md family, are interspersed throughout the mouse albumin and alpha-fetoprotein gene complex. Unlike those of the beta-globin complex, all of which are found in the intergenic regions, these sequences are localized within intron 12 of the albumin gene and intron 3 of the AFP gene as well as twice in the 13.5 kbp intergenic region that links the albumin gene to the AFP gene.
- Published
- 1984
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.